Search

everythinglearnresearchcommunity

for

Search:↓

Early-onset male baldness may indicate a higher risk of prostate cancer.

Breast cancer survivors often face body image and sexual health issues, needing ongoing support and open communication with healthcare providers.

Male pattern baldness is linked to a higher risk of certain skin cancers, especially on the scalp.

Baldness (androgenic alopecia) could be a risk factor for prostate cancer.

Childhood cancer diagnosis leads to long-term physical and emotional health issues in parents.

Patients with nonmelanoma skin cancers are most bothered by fear of progression, appearance concerns, and having cancer.

New skin lesions on the scrotum or vulva in patients with a history of internal cancer could indicate rare skin metastasis.

Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.

A pathway helps maintain long telomeres in both stem and cancer cells.

Men with early hair loss may have a higher risk of enlarged prostate and possibly prostate cancer due to shared hormonal factors.

Male pattern baldness may predict prostate cancer risk.

Eating more omega-3 and less omega-6 fatty acids may lower the risk of developing prostate cancer.

Patients with metabolic syndrome had lower Gleason scores when diagnosed with prostate cancer.

The document suggests more research is needed to understand the link between baldness and prostate cancer.

Prostate cancer risk is not linked to blood testosterone levels.

Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.

CEC levels may be a useful marker for predicting prostate cancer progression.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.

ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.

The issue covers reproductive health topics like cancer markers, incontinence treatments, and the impact of pre-term birth.

Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Finasteride lowers PSA levels in men, certain factors increase testicular cancer risk, and current guidelines for penile cancer may lead to unnecessary surgeries.

Antioxidants can block the cancer-fighting effects of doxorubicin.

Higher BMI is linked to a lower risk of non-aggressive prostate cancer and a higher risk of aggressive prostate cancer.

Some supplements may help reduce side effects of cancer treatments in pets.

Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.

The cancer gene c-Myc increases harmful chemicals that damage DNA and can lead to cancer, but antioxidants can reduce this damage.

Long-term use of oral contraceptives, especially starting before age 20, may increase the risk of early-onset breast cancer.